[{"id":"da2a1d36-30db-440a-9df5-123b9dec43a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06502249","created_at":"2025-02-27T07:46:28.341Z","updated_at":"2025-02-27T07:46:28.341Z","phase":"","brief_title":"Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)","source_id_and_acronym":"NCT06502249","lead_sponsor":"Ain Shams University","biomarkers":" MYC • IL6 • STAT3 • HSP90AA1","pipe":"","alterations":" ","tags":["MYC • IL6 • STAT3 • HSP90AA1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2026","start_date":" 06/01/2026","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-07-16"},{"id":"ac38e7b9-aa0f-4c10-b443-8463b2fb4d72","acronym":"EDI-PIO","url":"https://clinicaltrials.gov/study/NCT02852486","created_at":"2022-04-24T08:57:48.167Z","updated_at":"2024-07-02T16:35:27.180Z","phase":"Phase 2","brief_title":"Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response","source_id_and_acronym":"NCT02852486 - EDI-PIO","lead_sponsor":"University of Campinas, Brazil","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2023-12-04"},{"id":"156d54c5-8d8f-476f-89e1-cf5c28672101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05098327","created_at":"2021-10-28T17:56:21.946Z","updated_at":"2024-07-02T16:35:39.988Z","phase":"Phase 3","brief_title":"Pioglitazone and Insulin Resistance in ADT","source_id_and_acronym":"NCT05098327","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AKT2 • IRS1 • TLR4 • MAPK8 • SOCS3","pipe":"","alterations":" ","tags":["AKT2 • IRS1 • TLR4 • MAPK8 • SOCS3"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-08-15"},{"id":"0c84ebb7-7fc4-41b0-89f2-110ac246df29","acronym":"","url":"https://clinicaltrials.gov/study/NCT02249949","created_at":"2021-01-23T05:52:29.927Z","updated_at":"2024-07-02T16:35:46.246Z","phase":"Phase 2","brief_title":"Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02249949","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" DDIT3","pipe":"","alterations":" ","tags":["DDIT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e efatutazone (CS-7017)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/04/2018","primary_completion_date":" 10/04/2018","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2023-06-07"},{"id":"5c302561-f0a1-45e2-b8b2-d9048216815e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013255","created_at":"2021-08-19T14:52:57.027Z","updated_at":"2024-07-02T16:36:07.350Z","phase":"Phase 2","brief_title":"Pioglitazone Therapy Targeting Fatigue in Breast Cancer","source_id_and_acronym":"NCT05013255","lead_sponsor":"West Virginia University","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/23/2021","start_date":" 12/23/2021","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2022-07-13"},{"id":"2b1be91c-a18a-4404-a539-c7f329a044ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04883125","created_at":"2021-05-12T11:53:34.575Z","updated_at":"2024-07-02T16:36:30.407Z","phase":"Phase 2","brief_title":"Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment","source_id_and_acronym":"NCT04883125","lead_sponsor":"Mansoura University","biomarkers":" ABL1 • BCR • EPAS1 • CITED2","pipe":"","alterations":" ","tags":["ABL1 • BCR • EPAS1 • CITED2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 04/15/2021","primary_completion_date":" 04/15/2021","study_txt":" Completion: 04/15/2021","study_completion_date":" 04/15/2021","last_update_posted":"2021-05-12"},{"id":"95e2fcd2-7528-4f46-8f55-3dec31eeebbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01655719","created_at":"2021-01-18T07:08:24.420Z","updated_at":"2024-07-02T16:37:16.829Z","phase":"Phase 2","brief_title":"Pioglitazone in Thyroid Cancers","source_id_and_acronym":"NCT01655719","lead_sponsor":"University of Michigan","biomarkers":" PPARG • PAX8 • TG","pipe":"","alterations":" ","tags":["PPARG • PAX8 • TG"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 03/31/2017","primary_completion_date":" 03/31/2017","study_txt":" Completion: 03/31/2017","study_completion_date":" 03/31/2017","last_update_posted":"2017-10-26"},{"id":"cc40bdbe-37b2-4036-8d3f-96cd3fbd7722","acronym":"","url":"https://clinicaltrials.gov/study/NCT03309319","created_at":"2021-01-18T16:20:37.062Z","updated_at":"2024-07-02T16:37:17.126Z","phase":"","brief_title":"A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas","source_id_and_acronym":"NCT03309319","lead_sponsor":"Zhaoyun Zhang","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rosiglitazone"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 10/16/2016","start_date":" 10/16/2016","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2017-10-13"},{"id":"b46ad567-e792-474c-8662-52333490ff82","acronym":"ACTIM","url":"https://clinicaltrials.gov/study/NCT02888964","created_at":"2022-04-24T08:57:50.903Z","updated_at":"2024-07-02T16:37:29.274Z","phase":"Phase 2","brief_title":"Pioglityazone and Imatinib for CML Patients","source_id_and_acronym":"NCT02888964 - ACTIM","lead_sponsor":"Versailles Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2016-09-08"}]